Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

3322 - A Phase 1 Study to Evaluate the Safety and Tolerability of Bevacizumab-Niraparib Combination Therapy and Determine the Recommended Phase 2 Dose (RP2D) in Women with Platinum-Sensitive Epithelial Ovarian Cancer (ENGOT-OV24/AVANOVA1)


09 Sep 2017


Poster display session


Mansoor Raza Mirza


Annals of Oncology (2017) 28 (suppl_5): v330-v354. 10.1093/annonc/mdx372


M.R. Mirza1, J. Wang2, M. Mau-Sørensen3, M.J. Birrer4, X. Wang2, M. Jørgensen5, Z. Zhang6, H. Roed5, S. Malander7, F. Nielsen8, L. Bjørge9, U. Lassen10, L. Boufercha5, K. Brøsen8, V. Kansra2, J. Mäenpää11

Author affiliations

  • 1 Oncology, Nordic Society of Gynecologic Oncology (NSGO) and Rigshospitalet, Copenhagen University Hospital, 2200 - Copenhagen/DK
  • 2 Clinical Pharmacology, TESARO, Inc., Waltham/US
  • 3 Oncology, Rigshospitalet, 2100 - Copenhagen/DK
  • 4 Gynecologic Oncology, Massachusetts General Hospital, 2114 - Boston/US
  • 5 Oncology, Nordic Society of Gynecologic Oncology (NSGO) and Rigshospitalet, 2200 - Copenhagen/DK
  • 6 Clinical Pharmacology, TESARO, Inc., 02451 - Waltham/US
  • 7 Oncology, The Nordic Society of Gynecological Oncology (NSGO) & Lund University Hospital, Lund/SE
  • 8 Clinical Pharmacology And Pharmacy, Department of Public Health, Environmental Medicine, University of Southern Denmark, Odense/DK
  • 9 Clinical Science, University of Bergen, Bergen/NO
  • 10 Oncology, Rigshospitalet, 2100   - Copenhagen/DK
  • 11 Obstetrics And Gynecology, University of Tampere and Tampere University, Tampere/FI


Abstract 3322


A phase 2 randomized study has indicated that the combination of a poly(ADP-ribose) polymerase inhibitor (PARPi) with an anti-angiogenic drug is superior to PARPi alone.


Bevacizumab 15 mg/kg IV q 21 days (fixed dose) was administered with escalating dose of niraparib capsules (100, 200, 300 mg daily) in a classic 3 + 3 escalation design. Platinum-sensitive ovarian cancer patients (pts) with high-grade serous/endometrioid carcinoma and with measurable disease (RECIST or GCIG criteria) were eligible. The primary objective was to evaluate the safety and tolerability of the bevacizumab-niraparib combination therapy and determine the RP2D of bevacizumab-niraparib.


Twelve pts (3 + 3+6) were enrolled to three dose levels. Three of 12 pts had gBRCA2 mutation, while the others were non-gBRCAmut. During the first cycle, patients experienced hypertension (G3=5 pts), anemia (G3=3 pts), thrombocytopenia (G3=1 pt), fatigue (G2=1 pt), constipation (G2=1 pt), and nausea (G2=1 pt). One dose-limiting toxicity (Grade 3 thrombocytopenia that persisted for ≥5 days) was observed at the highest dose level, and the RP2D is therefore bevacizumab 15 mg/kg with niraparib capsules 300 mg. Niraparib dose reductions occurred in four pts (cohort 2=1 pt; cohort 3=3 pts), and bevacizumab termination occurred in two pts. Three pts are still on treatment, while nine pts have discontinued treatment (8 progressive disease; 1 withdrawal of consent). Disease control rate was 91%, and response rate was 45% (1 CR; 4 PR). Niraparib pharmacokinetics were consistent with historical data. Overlapping exposure was observed across the dose range tested at both C1D1 and C2D1.


The bevacizumab-niraparib combination has hematologic dose-limiting toxicity and expected, manageable class toxicities with preliminary evidence of efficacy. The PK profiles of niraparib co-administered with bevacizumab are similar to historical data. A phase 2 randomized 2-arm trial is ongoing (AVANOVA2, NCT02354131).

Clinical trial identification


Legal entity responsible for the study

Nordic Society for Gynaecologic Oncology




M.R. Mirza: Advisory board: Tesaro, Roche, AstraZeneca & Clovis Oncology. J. Wang, X. Wang, Z-Y. Zhang, V. Kansra: Employment: Tesaro; Stock: Tesaro. M. Mau-Sørensen: Research grants and support to participate in conferences from Roche. S. Malander: Honoraria: AstraZeneca, Roche. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.